WCRC

WCRC Researched Brand · World's Most Powerful Brands 2026 · Second Global Mega Edition

Lilly

Main author: · Chairman, WCRC

Lilly, the brand of Eli Lilly and Company, is a US pharmaceutical group whose portfolio is led by the diabetes and obesity medicines Mounjaro and Zepbound, alongside diabetes and oncology franchises. Revenue rose 45% to US$65.2bn in 2025, net income reached US$20.6bn, and the company has guided to US$80-83bn for 2026. It holds credit ratings in the A and AA ranges with stable outlooks. WCRC's research found the brand strongest in its competitive financial position, in an innovation pipeline backed by US$13.3bn of R&D spending across incretin, Alzheimer's and oncology programmes, and in its strategic relevance as a leader in obesity and cardiometabolic care, where record patient demand is driving growth.

Region
Americas
Country
United States
WCRC status
Researched brand

What WCRC found

  1. Dominant financial position in its sector, with 2025 net income of US$20.6bn on US$65.2bn revenue.

  2. Deep research pipeline funded by US$13.3bn of R&D spending, spanning incretin, Alzheimer's and oncology medicines.

  3. Strong future relevance through obesity and cardiometabolic leadership, with 2026 revenue guided to US$80-83bn.

What holds it back: As a prescription drug maker, Lilly has limited emotional connection with consumers, and drug-pricing criticism tempers public goodwill despite strong patient demand.

Status in the 2026 edition

Lilly was researched by WCRC for the 2026 edition. It is not among the 100 ranked brands.

WCRC publishes scores only for the 100 ranked brands. Evidence and detailed findings are available on request at consulting@wcrcint.com.

Get your WCRC brand report

The report covers your scores on all 50 parameters, a pillar-by-pillar comparison with sector rivals, your strengths and gaps, five-year financial performance, and marketing rights to use the findings.

Contact us at consulting@wcrcint.com

Contact us

Questions people ask

Is Lilly in the WCRC World's Most Powerful 100 Brands 2026?

Lilly was researched by WCRC for the 2026 edition. It is not among the 100 ranked brands.

Which Healthcare & Life Sciences brands are ranked in 2026?

No Healthcare & Life Sciences brand reached the 2026 top 100.

Evidence-led review

Appeal or request a ranking correction.

Have evidence about a published ranking or brand assessment? Tell WCRC what needs review and link the supporting sources. Corrections and appeals are free.

Submit a correction or appeal →